Program
empagliflozin
Also written as “BI 10773”, “Empagliflozin” and “BI10773”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Heart Failure · Diabetes Mellitus, Type 1 · Renal Insufficiency, Chronic · Diabetes Mellitus, Lipoatrophic, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 992 open or running | phase 4since Oct 27, 2015 | Nov 14, 2007 | Dec 11, 2026phase 1 · NCT07845630 |
| ADIUM | 40 open or running | no phasesince Mar 9, 2026 | Mar 9, 2026 | none ahead |
| Getz Pharma | 41 open or running | phase 4since Nov 27, 2020 | Nov 27, 2020 | Dec 31, 2026phase 4 · NCT05164263 |
| Gedeon Richter Plc. | 30 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Chong Kun Dang Pharmaceutical | 21 open or running | phase 4since Jan 15, 2026 | Aug 1, 2016 | Aug 2027phase 4 · NCT07365358 |
| Dong Wha Pharmaceutical | 20 open or running | phase 1since Apr 10, 2023 | Apr 10, 2023 | none ahead |
| Kobe University | 20 open or running | phase 3since Jul 10, 2019 | Jul 10, 2019 | none ahead |
| Celltrion | 11 open or running | phase 3since Jun 30, 2025 | Jun 30, 2025 | Dec 2026phase 3 · NCT07093476 |
| Dong-A ST | 10 open or running | phase 1since Dec 5, 2018 | Dec 5, 2018 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Nov 16, 2021 | Nov 16, 2021 | none ahead |
| hyundai-pharm | 11 open or running | phase 1since Jul 4, 2024 | Jul 4, 2024 | none ahead |
| Intarcia Therapeutics | 10 open or running | phase 3since Feb 9, 2017 | Feb 9, 2017 | none ahead |
| Nabiqasim Industries (Pvt) | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| pharma-nueva | 11 open or running | phase 1since Mar 6, 2024 | Mar 6, 2024 | none ahead |
| Profil Institut für Stoffwechselforschung | 10 open or running | phase 4since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Oct 27, 2014.
- Dec 10, 2024Gedeon Richter Plc.'s first study: phase 1 study in Diabetes Mellitus, Type 2New to Gedeon Richter Plc.Gedeon Richter Plc. · NCT06766500 · 64 enrolled · Russian Federation
- Jan 20, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06792968 · 64 enrolled · Russian Federation
- Feb 7, 2025Phase 1 study in Diabetes Mellitus, Type 2Gedeon Richter Plc. · NCT06823856 · 64 enrolled · Russian Federation
- Feb 19, 2025Nabiqasim Industries (Pvt)'s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan
- Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT06926660 · 492 enrolled · United States, Argentina, Australia and more
- Apr 30, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT06962826 · 14 enrolled · Germany
- Jun 17, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT07035457 · 15 enrolled · Germany
- Jun 30, 2025Celltrion's first study: phase 3 study in Diabetes Mellitus, Type 2New to CelltrionCelltrion · NCT07093476 · 171 planned · South Korea
- Aug 5, 2025Phase 3 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT07107945 · 135 enrolled · United States, Argentina, Australia and more
- Aug 19, 2025Phase 1 study in HealthyBoehringer Ingelheim · NCT07133399 · 32 enrolled · Germany
- Jan 15, 2026Phase 4 study in Diabetes Mellitus, Type 2Chong Kun Dang Pharmaceutical · NCT07365358 · 200 planned · South Korea
- Mar 9, 2026ADIUM's first study: no phase study in BioequivalanceNew to ADIUMADIUM · NCT07479108 · 32 enrolled · Mexico
- Jun 3, 20263 no phase studies in Bioequivalence Study in Healthy SubjectsADIUM · NCT07633054, NCT07633041, NCT07633028
- Sep 23, 2026Phase 1 study in HealthyBoehringer Ingelheim · NCT07845630 · 36 planned · Germany
Ahead
- Dec 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 2Celltrion · NCT07093476
- Dec 11, 2026Primary completion: phase 1 study in HealthyBoehringer Ingelheim · NCT07845630
- Dec 31, 2026Primary completion: phase 4 study in Diabetes Mellitus, Type 2Getz Pharma · NCT05164263
- Apr 16, 2027Primary completion: phase 3 study in Renal Insufficiency, ChronicBoehringer Ingelheim · NCT07107945
TargetBeta
“An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dapagliflozin | AstraZeneca | phase 4 | 133 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 25 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
The newest 60 of 124 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07845630Healthy · Germany | 1 | Recruiting | Boehringer Ingelheim | Dec 11, 2026 | 36 |
| NCT07633054Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Nov 24, 2025 | 42 |
| NCT07633041Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Apr 4, 2025 | 42 |
| NCT07633028Bioequivalence Study in Healthy Subjects · Mexico | – | Completed | ADIUM | Apr 8, 2025 | 42 |
| NCT07479108Bioequivalance · Mexico | – | Completed | ADIUM | Dec 11, 2024 | 32 |
| NCT07365358Diabetes Mellitus, Type 2 · South Korea | 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | Aug 2027 | 200 |
| NCT07133399Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Oct 22, 2025 | 32 |
| NCT07107945Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Boehringer Ingelheim | Apr 16, 2027 | 135 |
| NCT07093476Diabetes Mellitus, Type 2 · South Korea | 3 | Recruiting | Celltrion | Dec 2026 | 171 |
| NCT07035457Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Aug 7, 2025 | 15 |
| NCT06962826Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 26, 2025 | 14 |
| NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Boehringer Ingelheim | Aug 14, 2026 | 492 |
| NCT06862739Diabetes Mellitus · Pakistan | 4 | Recruiting | Nabiqasim Industries (Pvt) | Apr 30, 2026 | 800 |
| NCT06823856Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | May 21, 2025 | 64 |
| NCT06792968Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | Apr 6, 2025 | 64 |
| NCT06766500Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | Gedeon Richter Plc. | Feb 28, 2025 | 64 |
| NCT06578676Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Recruiting | hyundai-pharm | Sep 2, 2024 | 56 |
| NCT06308679Healthy Vollunteer | 1 | Not yet recruiting | pharma-nueva | May 31, 2024 | 28 |
| NCT05823883DW6014 · Korea, Republic of | 1 | UNKNOWN | Dong Wha Pharmaceutical | Jul 2023 | 30 |
| NCT05823870Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Mar 6, 2023 | 32 |
| NCT05359432Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | Getz Pharma | Aug 10, 2021 | 120 |
| NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Boehringer Ingelheim | Jun 19, 2023 | 714 |
| NCT05164263Diabetes Mellitus, Type 2 · Afghanistan, Kenya, Nigeria and more | 4 | Recruiting | Getz Pharma | Dec 31, 2026 | 2,000 |
| NCT05132023Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Apr 2, 2019 | 26 |
| NCT05083949Healthy · Brazil | 1 | Completed | Boehringer Ingelheim | Aug 6, 2021 | 32 |
| NCT04976283Diabetes Mellitus, Type 2 · Pakistan | 4 | UNKNOWN | Getz Pharma | May 15, 2023 | 123 |
| NCT04665284Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | Getz Pharma | Sep 15, 2020 | 244 |
| NCT04531462Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Boehringer Ingelheim | Aug 19, 2022 | 129 |
| NCT04509674Myocardial Infarction · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Nov 5, 2023 | 6,522 |
| NCT04233801Diabetes Mellitus, Type 2 · China | 3 | Completed | Boehringer Ingelheim | Mar 3, 2022 | 219 |
| NCT04221152Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans · Japan | 3 | UNKNOWN | Kobe University | Feb 1, 2022 | 8 |
| NCT04157751Heart Failure · United States, Belgium, Canada and more | 3 | Completed | Boehringer Ingelheim | May 28, 2021 | 530 |
| NCT04018365Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans · Japan | 3 | UNKNOWN | Kobe University | Jul 31, 2021 | 8 |
| NCT03766724Type2 Diabetes · Korea, Republic of | 1 | Completed | Dong-A ST | Jan 18, 2019 | 42 |
| NCT03629054Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 5, 2018 | 30 |
| NCT03594110Renal Insufficiency, Chronic · United States, Canada, China and more | 3 | Completed | Boehringer Ingelheim | Jul 5, 2022 | 6,609 |
| NCT03448419Heart Failure · United States, Australia, Canada and more | 3 | Completed | Boehringer Ingelheim | Sep 30, 2019 | 312 |
| NCT03448406Heart Failure · United States, Australia, Canada and more | 3 | Completed | Boehringer Ingelheim | Oct 4, 2019 | 315 |
| NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Boehringer Ingelheim | Oct 19, 2022 | 175 |
| NCT03332212Heart Failure · United Kingdom | 3 | Completed | Boehringer Ingelheim | May 21, 2020 | 72 |
| NCT03259490Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 13, 2017 | 30 |
| NCT03254849Diabetes Mellitus, Type 2 · Germany | 4 | Completed | Profil Institut für Stoffwechselforschung | Apr 20, 2020 | 75 |
| NCT03057977Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | May 1, 2020 | 3,730 |
| NCT03057951Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Boehringer Ingelheim | Apr 26, 2021 | 5,988 |
| NCT03060980Diabetes Mellitus, Type 2 · United States, Canada | 3 | Terminated | Intarcia Therapeutics | Jan 26, 2018 | 245 |
| NCT02854748Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | Chong Kun Dang Pharmaceutical | Sep 2016 | 30 |
| NCT02821910Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Oct 1, 2016 | 50 |
| NCT02815644Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Oct 5, 2016 | 22 |
| NCT02782624Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 2009 | 16 |
| NCT02758171Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 29, 2016 | 56 |
| NCT02702011Diabetes Mellitus, Type 1 · Japan | 2 | Completed | Boehringer Ingelheim | Sep 5, 2016 | 48 |
| NCT02632747Diabetes Mellitus, Type 1 · Canada | 2 | Completed | Boehringer Ingelheim | Dec 19, 2017 | 31 |
| NCT02589639Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Boehringer Ingelheim | Apr 18, 2017 | 269 |
| NCT02589626Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Boehringer Ingelheim | Jun 2, 2017 | 65 |
| NCT02580591Diabetes Mellitus, Type 1 · United States, Australia, Canada and more | 3 | Completed | Boehringer Ingelheim | Sep 12, 2017 | 977 |
| NCT02577315Healthy · Russian Federation | 1 | Completed | Boehringer Ingelheim | Oct 2015 | 25 |
| NCT02489968Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Boehringer Ingelheim | Nov 18, 2016 | 880 |
| NCT02453555Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Boehringer Ingelheim | Aug 26, 2016 | 275 |
| NCT02414958Diabetes Mellitus, Type 1 · United States, Australia, Austria and more | 3 | Completed | Boehringer Ingelheim | Apr 20, 2017 | 730 |
| NCT02276365Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 20 |
How it is read
Names in the registry
- “BI 10773”, 71 entries
- “Empagliflozin”, 53 entries
- “BI10773”, 7 entries
- “Empagliflozin/Metformin”, 4 entries
- “Empagliflozin + Linagliptin”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 67 studies
- Heart Failure, 6 studies
- Diabetes Mellitus, Type 1, 5 studies
- Renal Insufficiency, Chronic, 4 studies
- Diabetes Mellitus, Lipoatrophic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.